Schizoaffective disorder - A conglomerated disorder that needs an amalgamation of ideas

The continued use of schizoaffective disorder (SAD) as a diagnostic category remains puzzling, given its well-documented lack of validity, reliability, and clinical utility. In practice, the reflexive application of this diagnosis to patients presenting with features of both schizophrenia and a mood disorder (MD) undermines the potential for personalised care and often leads to unnecessary prescription of psychotropic medications, without adequate reassessment of diagnosis or treatment. While criticisms of SAD have typically centred upon its nosological weaknesses, far less attention has been paid to its broader implications for clinical care and psychiatric research. In this paper, we critically examine the reasons SAD fails to meet the criteria of a legitimate medical diagnosis and explore the downstream consequences of its continued use-particularly in terms of clinical outcomes and the integrity of population and treatment response data. Notably, studies claiming to investigate schizophrenia frequently include patients diagnosed with SAD, thereby introducing heterogeneity that compromises the clarity and reliability of findings. We refer to this as diagnostic conglomeration and argue that the flawed conceptual foundation of SAD has far-reaching ramifications for illness detection, research quality, and therapeutic decision-making. Acknowledging the absence of compelling evidence for the validity of SAD as a discrete entity, we contend that this issue of diagnostic ambiguity that stems from the illogical amalgamation of disorders demands reconsideration-both in study design and clinical practice- if we are to enhance care for the many patients burdened by this problematic diagnosis.